Literature DB >> 9180162

Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator.

G Frenette1, R R Tremblay, C Lazure, J Y Dube.   

Abstract

Our work was undertaken to compare the relative efficiency of 2 purified prostatic kallikreins, namely, hK2 and prostate-specific antigen (PSA or hK3), in the activation of single-chain urokinase (scuPA). We found that hK2 converts scuPA into an active enzyme with an efficiency equal to approximately 1/50 that of plasmin. During the activation of scuPA by hK2, two fragments of 33 and 22 kDa were generated. The NH2-terminal amino acid sequence of the 33 kDa fragment showed that hK2 cleaved scuPA between Lys158 and Ile159. In contrast to a previous report by another group, our purified hK3 preparation containing no trypsin-like contaminants was totally unable to activate scuPA. Our results show that kallikrein hK2 has plasmin-like activity and suggest that it could be the initiator of a proteolytic cascade leading to prostatic cancer invasion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180162     DOI: 10.1002/(sici)1097-0215(19970529)71:5<897::aid-ijc31>3.0.co;2-2

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  The impact of hypoxemia on serum total and free prostate-specific antigen levels in patients with chronic obstructive pulmonary disease.

Authors:  Cengiz Ozge; Murat Bozlu; Eylem Sercan Ozgur; Mesut Tek; Ahmet Tunckiran; Necati Muslu; Ahmet Ilvan
Journal:  Med Oncol       Date:  2015-04-03       Impact factor: 3.064

Review 2.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

Review 3.  Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

Authors:  Daniel L J Thorek; Michael J Evans; Sigrid V Carlsson; David Ulmert; Hans Lilja
Journal:  Thromb Haemost       Date:  2013-08-01       Impact factor: 5.249

Review 4.  Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis.

Authors:  Michael Blaber; Hyesook Yoon; Maria A Juliano; Isobel A Scarisbrick; Sachiko I Blaber
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

5.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

6.  Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.

Authors:  Hyesook Yoon; Sachiko I Blaber; D Michael Evans; Julie Trim; Maria Aparecida Juliano; Isobel A Scarisbrick; Michael Blaber
Journal:  Protein Sci       Date:  2008-08-12       Impact factor: 6.725

7.  Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity.

Authors:  Wolfgang Skala; Daniel T Utzschneider; Viktor Magdolen; Mekdes Debela; Shihui Guo; Charles S Craik; Hans Brandstetter; Peter Goettig
Journal:  J Biol Chem       Date:  2014-10-16       Impact factor: 5.157

8.  Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.

Authors:  Prashant D Tailor; Sai Karthik Kodeboyina; Shan Bai; Nikhil Patel; Shruti Sharma; Akshay Ratnani; John A Copland; Jin-Xiong She; Ashok Sharma
Journal:  Oncotarget       Date:  2018-04-03

9.  Network of clinically-relevant lncRNAs-mRNAs associated with prognosis of hepatocellular carcinoma patients.

Authors:  Lee Jin Lim; Yu Jin; Henry Yang; Alexander Y F Chung; Brian K P Goh; Pierce K H Chow; Chung Yip Chan; William K Blanks; Peng Chung Cheow; Ser Yee Lee; Tony K H Lim; Samuel S Chong; London L P J Ooi; Caroline G Lee
Journal:  Sci Rep       Date:  2020-07-07       Impact factor: 4.379

10.  Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.

Authors:  K Oikonomopoulou; L Li; Y Zheng; I Simon; R L Wolfert; D Valik; M Nekulova; M Simickova; T Frgala; E P Diamandis
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.